Abstract: A computer implemented method for prescribing optimized medical interventions includes retrieving a patient's updated electronic medical record (EMR) and mapping the diagnosis of the patient to a medical treatment database to select a plurality of likely medical intervention choices based on a score exceeding a defined threshold score. The method includes determining a rank order of the selected plurality of medical intervention choices by comparing simulation outcomes for each choice executed by the medical predictive algorithm, on respective choices among each of the selected likely medical interventions. The method also includes receiving by the patient's physician or patient's electronic medical record database, a rank order of recommended medical intervention choices including possible options and associated metrics based on an accepted level of simulated outcome.

Abstract: A novel process for preparation of Deutetrabenazine ((RR, SS)-1,3,4,6,7-11b-Hexahydro-9,10-di(methoxy-d6)-3-(2-methylpropyl)-2H-benzo [a] quinolizin-2-one) of formula I comprises of methylation of N-(2-(3,4-dihydroxy-phenyl)-ethyl)-formamide compound of formula III with deuteriated methanol (CD3OD or CD3OH) to obtain d6-N-(2-(3,4-dimethoxy-phenyl)-ethyl)-formamide compound of formula IV; cyclization of d6-N-(2-(3,4-dimethoxy-phenyl)-ethyl)-formamide in presences of dehydrating agent to obtain d6-6,7-Dimethoxy-3,4-dihydroisoquinoline compound of formula V; reacting d6-6,7-Dimethoxy-3,4-dihydroisoquinoline compound of formula V with 2-acetyl-N,N,N,4-tetramethyl-1-pentanaminium iodide compound of formula VI.

Abstract: The present invention is directed to a system for monitoring the functional status of an implantable heart valve. The system includes wireless pressure sensors that are embedded in the implantable heart valve. An external device receives signal transmitted from the wireless pressure sensors. The external device reads and analyzes these signals and then transmits the data to a healthcare provider.

Abstract: Embodiments herein disclose systems, methods, and computer-readable media for integrating facial recognition technology into clinical workflows. An application can manage receipt of a source image, including a face of an unidentified individual, and communicate the source image for facial recognition processing. The facial recognition processing can identify an individual and demographic information associated thereto, as well as provide information to access an electronic health record server housing one or more electronic health records. The application can access health-related data for the individual from the individual's EHR and rank the accessed information to communicate to a source device in a custom, prioritized communication.

Abstract: Embodiments herein disclose systems, methods, and computer-readable media for integrating facial recognition technology into clinical workflows. An application can manage receipt of a source image, including a face of an unidentified individual, and communicate the source image for facial recognition processing. The facial recognition processing can identify an individual and demographic information associated thereto, as well as provide information to access an electronic health record server housing one or more electronic health records. The application can access health-related data for the individual from the individual's EHR and rank the accessed information to communicate to a source device in a custom, prioritized communication.

Abstract: A transcatheter prosthetic heart valve includes a stent frame and a leaflet material. The stent frame includes a top portion and a bottom portion. The leaflet material includes a lower portion attached to the stent frame and an upper portion that includes leaflets capable of moving between an open configuration and a closed configuration. At least a portion of the leaflet material weaves through the stent frame. The transcatheter prosthetic heart valve also includes one or more reinforcement components coupled to the stent frame and/or to the leaflet material to enhance performance of the transcatheter heart valve.

Abstract: A transcatheter prosthetic heart valve includes a stent frame and at least one sheet of leaflet material formed in to a tube, which includes a lower portion disposed on an exterior of the stent frame and an upper edge portion disposed within the stent frame. The upper edge portion includes at least a portion configured to wrap around a first portion of the top edge of the stent frame and fold towards an exterior of the stent frame. The upper edge portion also includes at least another portion configured to weave through the stent frame and fold towards the interior of the stent frame.

Abstract: A transcatheter prosthetic heart valve includes a stent frame and at least one sheet of leaflet material formed in to a tube, which includes a lower portion disposed on an exterior of the stent frame and an upper edge portion disposed within the stent frame. The upper edge portion includes at least a portion configured to wrap around a first portion of the top edge of the stent frame and fold towards an exterior of the stent frame. The upper edge portion also includes at least another portion configured to weave through the stent frame and fold towards the interior of the stent frame.

Abstract: Methods for determining likelihood of thrombosis based on patient-specific anatomic, valve, and flow parameters are disclosed herein. Such methods are used to select a transcatheter aortic valve that decreases likelihood of thrombosis after TAVR procedures. The methods correlate a number of fluid flow and geometric parameters such as stasis volume, neo-sinus volume, kinematic viscosity, dynamic viscosity, heart rate, the circulation, ejection time, velocity of the main jet, wall shear stress, total kinetic energy in the neo sinus volume, width of the neo-sinus, height or depth of the neo-sinus, the angle between the velocity direction and the stent of the transcatheter valve, the distance from the tip of the leaflet perpendicular to the leaflet edge and intersecting the sinotubular junction, and the cross-sectional area of the neo-sinus taken from a longitudinal or axial perspective. Such parameters are used to derive empirical or semi-empirical mathematical models to determine the likelihood of thrombosis.

Abstract: A prosthetic heart valve includes a first upper frame portion and a stent frame connected to the first upper frame portion via at least two stent frame extensions. The stent frame includes a base and at least two stent posts extending upwardly from the base towards the first upper frame portion. The first upper frame portion, the base, and the at least two stent posts each has an inner surface and an outer surface. The prosthetic heart valve also includes at least one sheet of leaflet material configured to encircle the stent frame and weave through the stent frame between the first upper frame portion and the base.

Abstract: A transcatheter prosthetic heart valve includes a stent frame and at least one sheet of leaflet material formed in to a tube, which includes a lower portion disposed on an exterior of the stent frame and an upper edge portion disposed within the stent frame. The upper edge portion includes at least a portion configured to wrap around a first portion of the top edge of the stent frame and fold towards an exterior of the stent frame. The upper edge portion also includes at least another portion configured to weave through the stent frame and fold towards the interior of the stent frame.

Abstract: A method includes receiving code for computer programming, analyzing the code and extracting a plurality of configuration properties from the code. In the method, one or more configuration files are generated from the extracted plurality of configuration properties, and microservice code is generated from the one or more configuration files. The microservice code is configured for deployment on one or more cloud computing platforms.

Abstract: A novel process for preparation of Deutetrabenazine ((RR, SS)-1,3,4,6,7-11b-Hexahydro-9,10-di(methoxy-d6)-3-(2-methylpropyl)-2H- benzo [a] quinolizin-2-one) of formula I comprises of methylation of N-(2-(3,4-dihydroxy-phenyl)-ethyl)-formamide compound of formula III with deuteriated methanol (CD3OD or CD3OH) to obtain d6-N-(2-(3,4-dimethoxy-phenyl)-ethyl)-formamide compound of formula IV; cyclization of d6-N-(2-(3,4-dimethoxy-phenyl)-ethyl)-formamide in presences of dehydrating agent to obtain d6-6,7-Dimethoxy-3,4-dihydroisoquinoline compound of formula V; reacting d6-6,7-Dimethoxy-3,4-dihydroisoquinoline compound of formula V with 2-acetyl-N,N,N,4-tetramethyl-1-pentanaminium iodide compound of formula VI.

Abstract: Embodiments herein disclose systems, methods, and computer-readable media for integrating facial recognition technology into clinical workflows. An application can manage receipt of a source image, including a face of an unidentified individual, and communicate the source image for facial recognition processing. The facial recognition processing can identify an individual and demographic information associated thereto, as well as provide information to access an electronic health record server housing one or more electronic health records. The application can access health-related data for the individual from the individual's EHR and rank the accessed information to communicate to a source device in a custom, prioritized communication.

Abstract: A decision intelligence system permits a data expert to input information to define business questions and a business knowledge model. A semantic ontology is generated from the business knowledge model. The business knowledge model is mapped to data sources and used to generate information for generating APIs for generating views of business data, such as machine generated data.

Abstract: The devices and systems are medical fluid treatment therapies. The device and systems are configured and capable of operating based on small volumes of fluids. The devices and systems include a pump configured for small volume of a fluid. The pump may include a first conduit configured for inflow of the fluid; a second conduit configured for outflow of the fluid; a fluid chamber configured to move the fluid through the pump; a diaphragm configured to force the fluid through the fluid chamber by indirectly exerting force on the fluid chamber; and a connector configured to removably attach the pump to a motor.

Abstract: The present invention relates to a process for preparation of 6-perdeoxy-6-per-chloro gamma-cyclodextrin which is a key intermediate useful in the synthesis of Sugammadex sodium. The present invention further relates to a process for preparation and purification of Sugammadex sodium.

Abstract: Provided herein is a composite, comprising: a polymer host selected from the group consisting of low-density polyethylene (LDPE), linear low-density polyethylene (LLDPE), polyethylene terephthalate (PET), polytetrafluoroethylene (PTFE), and polypropylene (PP), polyurethane, polycaprolactone (PCL), polydimethylsiloxane (PDMS), polymethylmethacrylate (PMMA), and polyoxymethylene (POM); and a guest molecule comprising hyaluronic acid; wherein the guest molecule is disposed within the polymer host, and wherein the guest molecule is covalently bonded to at least one other guest molecule. Also provided herein are methods for forming the composite, and blood-contracting devices made from the composite, such as heart valves and vascular grafts.

Abstract: The present invention relates to a process for preparation of 6-perdeoxy-6-per-chloro gamma-cyclodextrin which is a key intermediate useful in the synthesis of Sugammadex sodium. The present invention further relates to a process for preparation and purification of Sugammadex sodium.

Abstract: Racemization-free methods are disclosed for the synthesis of carfilzomib. Novel intermediates and methods of making carfilzomib employing fragment condensation using the novel intermediates are disclosed. Amorphous carfilzomib and methods of making same are disclosed.